区域多州社区医院系统中开窗腔内动脉瘤修复的采用与临床结局
本回顾性队列研究纳入2012年4月至2021年6月在一个5州医院系统内接受开窗腔内动脉瘤修复(FEVAR)的全部患者,共160例(占所有AAA修复的4.2%),由12家医院的34名外科医生完成。结果显示院内死亡率为1.3%,术后并发症发生率为16.9%,靶血管通畅率为95.6%;外科医生和医院经验在最初1至3例后对结局有小幅正面影响。
要点
- FEVAR占全部AAA修复的4.2%(160/3850),由12家医院的34名外科医生完成。
- 院内死亡率为1.3%(n=2),术后并发症发生率为16.9%(n=27),术后肾功能下降发生率为5.1%。
- 外科医生首例之后术中并发症的OR为0.16(95%CI 0.03-0.77,第2-3例)。
核心结论
- 本医院系统内FEVAR的临床结局优于既往发表的报告。
- 过去十年系统范围内FEVAR的采用增加了3倍,但本系统内仍仅有少数医院开展FEVAR。
- 本队列结果显示不良事件发生率低、技术效率高,外科医生和医院经验的影响较小,从而支持这一先进腔内技术作为复杂主动脉解剖患者替代开放修复的安全、有效且可推广的治疗选择。
研究设计与样本
- 回顾性队列研究,纳入2012年4月至2021年6月在一个5州医院系统内接受FEVAR的全部手术。
- 2012年至2021年间共3850例患者接受任何类型的AAA手术,其中160例(4.2%)接受FEVAR。
- FEVAR由12家医院的34名外科医生完成;按序贯病例序号将患者分为外科医生经验组和医院经验组。
- 采用逆概率加权和广义线性混合模型,校正人口学特征和合并症后分析风险校正结局。
主要发现
- FEVAR患者术中并发症发生率为18.8%(n=30),非计划辅助手术发生率为19.4%(n=31)。
- 院内死亡率为1.3%(n=2),术后并发症发生率为16.9%(n=27),术后肾功能下降发生率为5.1%。
- 术后早期(<30天)内漏发生率为15.3%(n=21),术后首次影像学检查靶血管通畅率为95.6%。
- 与外科医生首例相比,随着外科医生经验增加,手术时间、透视时间和估计失血量显著下降(P<.05)。
- 外科医生首例之后术中并发症的OR为0.16(95%CI 0.03-0.77,第2-3例);医院首1-3例之后,第4-8例的OR为0.19(95%CI 0.04-0.89),第9-49例的OR为0.12(95%CI 0.03-0.55)。
临床怎么用
- 作者认为,FEVAR不良事件发生率低、技术效率高,外科医生和医院经验的影响较小,支持其作为复杂主动脉解剖患者替代开放修复的安全、有效且可推广的治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Complex endovascular abdominal aortic aneurysm (AAA) repair techniques have evolved over the last decade, yet patterns of physician and hospital system adoption of fenestrated endovascular aneurysm repair (FEVAR) remain poorly defined. We investigated clinical outcomes, use trends, and surgeon and hospital experience for FEVAR in a large community hospital system. METHODS: We conducted a retrospective cohort study of all FEVAR procedures within our 5-state hospital system between April 2012 and June 2021. AAA repair volumes (open, EVAR, and FEVAR) were captured at the hospital and surgeon levels using Current Procedural Terminology and International Classification of Diseases codes. Clinical and outcomes data were collected for FEVAR patients. To consider if surgeon or hospital experience influenced outcomes, sequential case number was used to divide patients into surgeon experience and hospital experience groups. Inverse probability weighted and generalized linear mixed models, adjusted for demographics and comorbidities, were built to examine risk-adjusted outcomes for surgeon and hospital experience groups. RESULTS: Of 3850 patients treated with AAA procedures of any kind between 2012 and 2021, 160 (4.2%) underwent FEVAR. FEVAR procedures were performed by 34 different surgeons at 12 hospitals, with intraoperative complications and unplanned adjunctive procedures occurring in 18.8% (n = 30) and 19.4% (n = 31) of patients, respectively. Among FEVAR patients, in-hospital mortality was 1.3% (n = 2) and postoperative morbidity was 16.9% (n = 27). Renal function decline occurred postoperatively in 5.1% of patients. Early (<30 day) postoperative endoleaks occurred in 15.3% of patients (n = 21). Target vessel patency was 95.6% on initial postoperative imaging. Surgeon and hospital experience had a small positive impact on outcomes after the first one to three cases. Significant decreases in operative time, fluoroscopy time, and estimated blood loss were observed with increased surgeon experience, relative to a surgeon's first case (P < .05). There were lower odds of intraoperative complications after a surgeon's first case (odds ratio [OR], 0.16; 95% confidence interval [CI], 0.03-0.77, for cases 2-3) or after a hospital's first one to three cases (OR, 0.19; 95% CI, 0.04-0.89, for cases 4-8; OR, 0.12; 95% CI, 0.03-0.55 for cases 9-49). CONCLUSIONS: Clinical outcomes of FEVAR across our hospital system compare favorably with previously published reports. Although system-wide FEVAR adoption increased 3-fold over the last decade, FEVAR continued to be performed by a minority of hospitals in our system. The results from this cohort demonstrate low rates of adverse events, high rates of technical efficiency, and a small impact of surgeon and hospital experience, thereby supporting this advanced endovascular technology as a safe, efficacious, and generalizable treatment alternative to open repair for patients with complex aortic anatomy.
引用
- Ullery BW, Hanes D, Kirker EB, et al. Adoption and clinical outcomes of fenestrated endovascular aneurysm repair in a regional, multistate community hospital system. J Vasc Surg. 2024. PMID: 38431063. doi:10.1016/j.jvs.2024.02.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。